Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease

Julien Vaucher1*, Pedro Marques-Vidal2, Martin Preisig3, Gérard Waeber1†, and Peter Vollenweider1†

1Department of Medicine, Internal Medicine, CHUV and Faculty of Biology and Medicine, Bâtiment des Instituts, Etude CoLaus, 19, rue du Bugnon, Lausanne 1005, Switzerland; 2Institute of Social and Preventive Medicine (IUMSP), CHUV and Faculty of Biology and Medicine, Lausanne, Switzerland; and 3Department of Psychiatry, CHUV and Faculty of Biology and Medicine, Lausanne, Switzerland

Received 6 January 2014; revised 28 January 2014; accepted 29 January 2014; online publish-ahead-of-print 25 February 2014

Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) issued new guidelines on management of cardiovascular (CV) risk in primary prevention.1 They developed a new CV risk calculator [new pooled cohort atherosclerotic CV disease (CVD) risk equation] targeting individuals between 40 and 75 years and based on four American population-based cohorts.2,3 Statin treatment is recommended for individuals with an estimated 10-year risk of CVD ≥ 7.5%, including stroke. Conversely, the guidelines of the European Society of Cardiology (ESC) advocate the use of the SCORE equation for individuals aged between 40 and 65 years, and initiation of a statin treatment is recommended if the estimated 10-year risk of death from CVD is ≥ 5%.4 Whether applying the ACC/AHA guidelines has similar public health consequences as applying the ESC guidelines is currently unknown. Hence, we used the data from a large, population-based study, to assess the country-wide population and economic impact of these new guidelines, supposing full adherence to treatment recommendations.

Data from the Swiss CoLaus study, collected between 2003 and 2006 in 3297 participants (1854 women) aged 50–75 years, were used.5 Ten-year CVD risk was computed according to the Swiss SCORE (ESC) and the 2013 ACC/AHA risk equations; results were extrapolated to the Swiss population of the same age group. The Swiss SCORE equation has been validated in individuals up to 75 years of age. Daily cost of treatment was estimated using one widely used statin, i.e. atorvastatin.

The results are summarized in Table 1. Irrespective of the risk equation used, the prevalence of high-risk individuals increased considerably with age, exceeding 80% among participants aged over 70 years. Extrapolated to the Swiss population, applying the ACC/AHA guidelines more than doubled the prevalence of high-risk individuals (2.2-fold in men and 1.9 fold in women) relative to the SCORE function. The biggest differences were observed for age group 50–60 years, where the ACC/AHA guidelines led to a 30-fold increase in the number of high-risk individuals relative to the ESC guidelines. Full compliance with the ACC/AHA guidelines would also lead to an extra cost of treatment of 1.124 million CHF per day (410 million CHF, or 333.7 million €, per year).

We conclude that, relative to the ESC guidelines, the 2013 ACC/AHA guidelines lead to a considerable increase in the number of high-risk individuals susceptible of receiving statin treatment. This increase is particularly strong in the age group 50–60 years. One likely explanation for this discrepancy may be due to differences in the prevalence of CV risk factors between the USA and Europe.6,7 Consequently, if fully implemented, the ACC/AHA guidelines might lead to a considerable increase in primary prevention costs of CVD. Further studies are needed to validate the new ACC/AHA risk equation and to assess the cost-effectiveness of the ACC/AHA guidelines in non-US countries.

Authors’ contributions

J.V. collected data and wrote most of the article. P.M.V. made the statistical analyses and wrote part of the article; M.P. revised the article for important intellectual content; G.W. and P.V. were the initiators of this study and revised the article for important intellectual content. P.M.V. had full access to the data and is the guarantor of the study.

Funding

The CoLaus study was supported by grants from the Swiss National Science Foundation (grant no: FN 33CSCO-122661 and 70IA90-124930-1). The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

* Corresponding author. Tel: +41 213140346, Fax: +41 213148037, Email: julien.vaucher@chuv.ch
† G.W. and P.V. contributed equally to this manuscript and are therefore both to be considered as last authors.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals.permissions@oup.com
Table 1  Simulations of the population impact and of daily costs related to treatment with atorvastatin in Switzerland according to the European Society of Cardiology (ESC) or 2013 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines

<table>
<thead>
<tr>
<th>ESC</th>
<th>Swiss population</th>
<th>Population at risk a</th>
<th>Ratio ACC/AHA to ESC b</th>
<th>Daily cost of treatment c</th>
</tr>
</thead>
<tbody>
<tr>
<td>(50–60)</td>
<td>561 013</td>
<td>1 112 118</td>
<td>8976</td>
<td>30.6</td>
</tr>
<tr>
<td>(60–70)</td>
<td>429 528</td>
<td>878 389</td>
<td>204 026</td>
<td>2.1</td>
</tr>
<tr>
<td>(70–75)</td>
<td>176 448</td>
<td>381 755</td>
<td>175 389</td>
<td>1.0</td>
</tr>
<tr>
<td>All</td>
<td>1 814 130</td>
<td>3 655 462</td>
<td>388 391</td>
<td>2.2</td>
</tr>
</tbody>
</table>

ACC/AHA

| (50–60)     | 561 013          | 1 112 118            | 274 335                | 30.6                     |
| (60–70)     | 429 528          | 878 389              | 419 649                | 2.1                      |
| (70–75)     | 176 448          | 381 755              | 176 448                | 1.0                      |
| All         | 1 166 989        | 2 372 262            | 870 432                | 2.2                      |

a According to the ACC/AHA (new pooled cohort atherosclerotic CV disease risk equation) or ESC (Swiss SCORE equation) guidelines.
b Ratio of the number of subjects at risk according to ACC/AHA guidelines to the number of subjects at risk according to ESC guidelines. NA, not assessable.
c Expressed in 1000 CHF. To obtain €, multiply by 0.814; to obtain USD, multiply by 1.110. Currency exchange rates as of 3 January 2014 were applied.
d Fixed daily price independent of dosing (10–80 mg).

References